Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ ...

AM ETAUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: SAVA), a clinical-stage biotechnology company focused on ...

Cassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...

Cassava Sciences stock collapsed after an Alzheimer’s drug the company was testing failed to significantly help participants ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...

Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s ...

Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...

This week, Cassava Sciences reported the failure of its latest Phase III trial of its experimental drug, simufilam—a drug that allegedly got as far as it did due to poorly done and potentially ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...